Acetone → 4-[trans-(2-Hydroxycyclopentan-1-yl)oxy]-2-(1-piperazinyl)quinazoline monoacetate

HRID 1416446Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1416446
[OH:1][C@@H:2]1[CH2:6][CH2:5][CH2:4][C@H:3]1[O:7][C:8]1[C:17]2[C:12](=[CH:13][CH:14]=[CH:15][CH:16]=2)[N:11]=[C:10]([N:18]2[CH2:23][CH2:22][NH:21][CH2:20][CH2:19]2)[N:9]=1.CC(C)=[O:26]>>[C:8]([OH:26])(=[O:7])[CH3:17].[OH:1][C@@H:2]1[CH2:6][CH2:5][CH2:4][C@H:3]1[O:7][C:8]1[C:17]2[C:12](=[CH:13][CH:14]=[CH:15][CH:16]=2)[N:11]=[C:10]([N:18]2[CH2:19][CH2:20][NH:21][CH2:22][CH2:23]2)[N:9]=1

Komponenten

3

Edukt 2

HCID 180AcetoneHCID 154091264-[trans-(2-Hydroxycyclopentan-1-yl)oxy]-2-(1-piperazinyl)quinazoline

Produkt 1

HCID 675829364-[trans-(2-Hydroxycyclopentan-1-yl)oxy]-2-(1-piperazinyl)quinazoline monoacetate

Versuchsvorschrift

4-[trans-(2-Hydroxycyclopentan-1-yl)oxy]-2-(1-piperazinyl)quinazoline (cf. Example 1) (2.70 g) is dissolved in acetone (55 ml) with heating, and the solution is filtered, and to the filtrate is added acetic acid (0.52 ml), and the mixture is allowed to stand at room temperature. The precipitated crystals are separated by filtration to give 4-[trans-(2-hydroxycyclopentan-1-yl)oxy]-2-(1-piperazinyl)quinazoline monoacetate (3.00 g) as crystals.

Aufarbeitung

  1. temperaturewith heating
  2. filtrationthe solution is filtered
  3. additionto the filtrate is added acetic acid (0.52 ml)
  4. customto stand at room temperature
  5. customThe precipitated crystals are separated by filtration

Quellen und Nachweise

ORD-Eintrag
ord-0a52329be9fa468d8f75bb294df38491
Quelldatensatz
uspto-grants-1999_06
Patentnummer
US05912247

Notizen zur Reaktion

Wird geladen…